GET DAILY SIGNALSMaze Therapeutics (MAZE): Q3 2026 Earnings Preview – Pipeline Milestones Take Center Stage
Key Takeaways
- Maze Therapeutics (NASDAQ: MAZE) plans to release third-quarter 2026 results in early November, covering the period ended September 30, 2026.
- Wall Street consensus calls for a net loss of about $0.76 per share, with little to no license revenue anticipated.
- The second quarter of 2026 showed a net loss of $44.7 million, or $0.76 per share, and zero revenue.
- Focus remains on clinical progress with MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease.
- Cash, cash equivalents, and marketable securities stood at $494.9 million at the end of June 2026, funding operations into 2029.
Why This Quarter Matters for Maze
Maze Therapeutics develops small-molecule precision medicines targeting renal, cardiovascular, and metabolic conditions. As a clinical-stage company without approved products, its quarterly updates emphasize trial execution and cash management more than traditional revenue or earnings beats. The firm posted a $44.7 million net loss in Q2 2026, and similar results are expected now. With two Phase 2 programs advancing, the report should provide clarity on development timelines, spending patterns, and whether the $494.9 million cash balance can sustain the pipeline.
What Analysts Expect
Consensus estimates point to a net loss of roughly $0.76 per share for Q3 2026, with projections spanning from about $0.57 to $0.87. Revenue should remain minimal, as Maze relies on milestone payments rather than product sales. The prior quarter delivered a matching $0.76 loss with no revenue, while Q1 2026 included $20.0 million from a Shionogi milestone on MZE001. Given this irregular revenue profile, attention will center on R&D and G&A trends plus trial enrollment updates. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Sentiment and Positioning
Investor tone ahead of the release appears measured yet sensitive to volatility. Fourteen analysts cover the stock, all with buy or equivalent ratings and an average price target near $62.54, well above recent trading levels and below the 52-week high of $53.65. Options markets price in a low-double-digit move after the report, consistent with the event-driven nature of clinical-stage biotech names. Past updates have triggered sharp swings, so positioning reflects that reality. Risks include slower enrollment, elevated cash burn, or competition from Vertex Pharmaceuticals’ inaxaplin program in the APOL1 space.
Clinical and Financial Outlook
Investors will track clinical timelines closely. Lead candidate MZE829, a dual-mechanism APOL1 inhibitor, continues in the Phase 2 HORIZON trial for AMKD, with updated data on three cohorts expected in late 2026 or early 2027 and a pivotal study slated for the first half of 2027.
The second asset, MZE782, targets the SLC6A19 transporter in PKU and CKD. Phase 2 enrollment in PKU is active, with topline results due in 2027, while a separate CKD study is set to start in the first half of 2027.
On the financial side, the key question involves the pace of operating expense growth as both programs move forward together. R&D costs have increased steadily, and management anticipates ongoing losses. With $494.9 million in cash as of mid-2026 and a runway into 2029, liquidity appears adequate, though faster spending or delayed milestones could tighten that buffer. I’m watching expense trends, trial updates, and competitive developments for the clearest signals on the company’s path ahead.
Research Tools That Help
When evaluating names like MAZE, I find it useful to cross-check pipeline and peer data with Tickeron’s AI Screener. The platform lets me filter biotech stocks by fundamentals, technical patterns, and AI signals in one place, which speeds up the comparison process without replacing deeper fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for MAZE turns positive, indicating new upward trend
MAZE saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator turned positive. In 30 of the 33 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
MAZE moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MAZE crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 3 of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +9.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where MAZE advanced for three days, in 91 of 103 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 73 of 80 cases where MAZE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for MAZE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 12 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 16 of 21 cases where MAZE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MAZE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
MAZE broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.988) is normal, around the industry mean (2.904). P/E Ratio (-13.332) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (63.291) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MAZE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MAZE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement